H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Denali Therapeutics today and set a price target of $32.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Fein has given his Buy rating due to a combination of factors that highlight Denali Therapeutics’ strategic positioning and potential for growth. Denali is on the verge of launching tividenofusp, the first transferrin receptor (TfR)-enabled medicine, which is expected to establish a new therapeutic class. This launch not only represents a significant milestone for the company but also sets up a commercial framework that could support future enzyme replacement programs. The recent acquisition of Avidity further validates the industry’s growing recognition of TfR-based delivery as a robust method for tissue penetration, positioning Denali at the forefront of this transformative platform.
Additionally, Denali’s pipeline is progressing well, with tividenofusp nearing its PDUFA date and DNL126 completing Phase 1/2 enrollment, potentially paving the way for accelerated approval. The company’s innovative Transport Vehicle (TV) platform is seen as both clinically validated and commercially scalable, enhancing confidence in Denali’s ability to capitalize on its technological advancements. Furthermore, Denali’s filing of new INDs for programs targeting Alzheimer’s and Pompe disease underscores its expansion into neuromuscular and CNS spaces, addressing unmet needs and potentially broadening its market reach.
Fein covers the Healthcare sector, focusing on stocks such as Alector, Denali Therapeutics, and Palvella Therapeutics. According to TipRanks, Fein has an average return of 24.9% and a 52.49% success rate on recommended stocks.